# PharmaBio Corporation

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/pharmabio

- Industry: Pharmaceuticals
- Headquarters: Tokyo, Japan
- Website: www.pharmabio.co.jp/
- Total disclosed funding: $5M
- Latest round: Series B (Jan 8, 2018)
- Investors on record: 2

## About

PharmaBio Corporation is a Tokyo-based firm specializing in advanced therapies, focusing on regenerative medicine and cell-based therapies, providing development and manufacturing services for innovative medical solutions.Founded in 1978, PharmaBio Corporation is a Tokyo-based company that develops and manufactures regenerative medicine products. It has engaged in two significant deals, with the latest funding round being Series B in June 2020, where it raised JPY 560.000 mn from investors including TNP Group and The University of Tokyo Edge Capital Partners. The company has achieved a current valuation of JPY 7,231.346 mn.PharmaBio Corporation specializes in advanced therapies, focusing primarily on the development and manufacturing of regenerative medicine and cell-based therapies. Their core offerings include comprehensive regulatory support for the development of cell and tissue-derived pharmaceuticals, as well as contract development and manufacturing organization (CDMO) services compatible with Good Cell Therapy Practices (GCTP). The company's facilities are designed to support the production of regenerative medicine products, allowing clients to harness innovative treatments for a range of medical conditions, including age-related macular degeneration and other degenerative diseases. PharmaBio serves a diverse client base comprising pharmaceutical companies, research institutions, and healthcare providers across multiple regions, including Japan and potentially other markets in Asia and beyond, though specific geographical market details are not disclosed.PharmaBio's revenue model is primarily structured around contract manufacturing and development services, where clients engage the company to produce customized regenerative medicine products. These transactions are typically executed on a B2B basis, with clients including biotech firms and academic institutions seeking expertise in advanced therapeutic manufacturing. The pricing structure is based on the specific services rendered and the scale of production required, with clients entering into contracts that detail the scope of work, timelines, and deliverables. Signature offerings, such as the production of mesenchymal stem cell sheets for clinical trials, are integral to these transactions. The company's financial performance is closely tied to the growing demand for innovative therapies, particularly within the regenerative medicine sector, although specific revenue figures and detailed transaction data are not disclosed.In June 2020, PharmaBio Corporation raised JPY 560.000 mn from Alfresa Corporation for a minority stake, which will support its strategic initiatives, including the expansion of its product line and entry into new markets. The company plans to introduce new regenerative medicine products aimed at treating various medical conditions, although specific release dates are not yet disclosed. Additionally, it aims to expand its operations into broader Asian markets to enhance its reach and service offering.

## Funding rounds

- Series B, Jan 8, 2018, $5M — University of Tokyo Edge Capital Partners, TNP Group

## Investors

- University of Tokyo Edge Capital Partners (https://capitalatlas.ai/funds/university-of-tokyo-edge-capital-partners) — Series B
- TNP Group (https://capitalatlas.ai/funds/tnp-group) — Series B